On Nov 13, major Wall Street analysts update their ratings for $Bristol-Myers Squibb (BMY.US)$, with price targets ranging from $60 to $73.
Citi analyst Geoff Meacham maintains with a hold rating, and adjusts the target price from $55 to $60.
UBS analyst Trung Huynh maintains with a hold rating, and adjusts the target price from $54 to $60.
BMO Capital analyst Evan Seigerman upgrades to a buy rating, and adjusts the target price from $53 to $61.
Leerink Partners analyst David Risinger upgrades to a buy rating, and adjusts the target price from $55 to $73.
Furthermore, according to the comprehensive report, the opinions of $Bristol-Myers Squibb (BMY.US)$'s main analysts recently are as follows:
The unexpected update regarding emraclidine's Phase 2 from AbbVie has led to a revision of projections, with emraclidine being removed from the forecast model and an increase in Cobenfy estimates for Bristol Myers. As a result, the total revenue for 2033 is anticipated to rise by 7%. The overall conclusion is that this development does not alter the long-term revenue or earnings per share growth trajectory for either company.
The pivotal Phase 2 data for a competing firm's schizophrenia treatment was unexpectedly unsuccessful in showing a significant change from the baseline in the Positive and Negative Symptom Scale total score, which was anticipated to be a key asset from a major acquisition and was projected to generate substantial sales by the end of the decade, potentially rivaling Bristol Myers's own treatment. The outlook for Bristol Myers's treatment should be considerably improved in the long term, although there are still concerns about the loss of exclusivity in the near term.
The latest clinical outcomes for AbbVie's Emraclidine, failing to demonstrate a statistically significant benefit at the primary endpoint in its Phase 2 studies, have positioned Bristol Myers' Cobenfy in a favorable spot. With competitors facing setbacks due to underwhelming data, the focus is now solely on Bristol Myers to successfully launch Cobenfy.
Here are the latest investment ratings and price targets for $Bristol-Myers Squibb (BMY.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月13日，多家華爾街大行更新了$施貴寶 (BMY.US)$的評級，目標價介於60美元至73美元。
花旗分析師Geoff Meacham維持持有評級，並將目標價從55美元上調至60美元。
瑞士銀行分析師Trung Huynh維持持有評級，並將目標價從54美元上調至60美元。
BMO資本市場分析師Evan Seigerman上調至買入評級，並將目標價從53美元上調至61美元。
Leerink Partners分析師David Risinger上調至買入評級，並將目標價從55美元上調至73美元。
此外，綜合報道，$施貴寶 (BMY.US)$近期主要分析師觀點如下：
關於艾伯維公司emraclidine的第二階段意外更新導致了預測的修訂，emraclidine被從預測模型中刪除，並且布里斯托爾·邁爾斯的Cobenfy估計有所增加。因此，預計2033年的總營業收入將上升7%。總體結論是，這一進展並未改變兩家公司的長期營業收入或每股收益的增長軌跡。
競爭公司治療精神分裂症的關鍵第二階段數據意外未能顯示出與基線的顯著變化，Positive and Negative Symptom Scale總分被認爲是主要收購的重要資產，並預計到本十年末可產生可觀的銷售額，可能與布里斯托爾·邁爾斯自己的治療形成競爭。雖然布里斯托爾·邁爾斯的治療前景在長期內應會有顯著改善，但仍對近期失去獨佔性存在擔憂。
艾伯維公司Emraclidine最新的臨床結果未能在第二階段研究的主要終點上顯示出統計顯著的收益，這使得布里斯托爾·邁爾斯的Cobenfy處於有利位置。由於競爭對手面臨因數據不佳而導致的挫折，現在的焦點完全放在布里斯托爾·邁爾斯上，期待其成功推出Cobenfy。
以下爲今日4位分析師對$施貴寶 (BMY.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
